KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Preferred Stock Liabilities: 2009-2017

Historic Preferred Stock Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 7 years, with Mar 2017 value amounting to -$822.0 million.

  • Teva Pharmaceutical Industries' Preferred Stock Liabilities rose 0.12% to -$822.0 million in Q1 2017 from the same period last year, while for Mar 2017 it was -$822.0 million, marking a year-over-year increase of 0.12%. This contributed to the annual value of -$811.0 million for FY2016, which is 200.00% down from last year.
  • According to the latest figures from Q1 2017, Teva Pharmaceutical Industries' Preferred Stock Liabilities is -$822.0 million, which was down 1.36% from -$811.0 million recorded in Q4 2016.
  • In the past 5 years, Teva Pharmaceutical Industries' Preferred Stock Liabilities ranged from a high of $811.0 million in Q4 2015 and a low of -$900.0 million during Q1 2015.
  • In the last 3 years, Teva Pharmaceutical Industries' Preferred Stock Liabilities had a median value of -$811.0 million in 2016 and averaged -$545.7 million.
  • Over the last 5 years, Teva Pharmaceutical Industries' Preferred Stock Liabilities had its largest YoY gain of 26.06% in 2013, and its largest YoY loss of 350.36% in 2013.
  • Over the past 5 years, Teva Pharmaceutical Industries' Preferred Stock Liabilities (Quarterly) stood at -$347.0 million in 2013, then slumped by 74.71% to -$608.0 million in 2014, then slumped by 144.57% to $811.0 million in 2015, then slumped by 200.00% to -$811.0 million in 2016, then climbed by 0.12% to -$822.0 million in 2017.
  • Its last three reported values are -$822.0 million in Q1 2017, -$811.0 million for Q4 2016, and -$614.0 million during Q3 2016.